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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
related to various food(s)/food constituent(s) and ―anti-aging properties‖, ―maintenance of urinary 
tract‖, ―cardiovascular health‖, ―vascular and vein health‖, ―blood flow/vascular function‖, ―hormonal 
balance‖, prevention or treatment of prostate cancer, ―women’s health‖, ―menstrual health‖, 
―absorption of nutrients‖, improvement of the digestion of macronutrients (e.g. carbohydrates, 
proteins and lipids), ―digestive function‖, ―gut health‖, ―intestinal flora‖, increasing numbers of 
gastro-intestinal microorganisms, ―stomach health‖, ―powerful protectors of the stomach‖, reduction 
of gastric acid  , treatment of diarrhoea and/or vomiting, ―liver health‖, ―nervous system function‖, 
―mental energy‖, ―mental health‖, ―physical and mental health‖, ―physical performance‖, 
―overtraining and effort prevention‖, ―physical well-being‖, ―skin health‖, maintenance of normal 
structure and appearance of hair and nails structure, maintenance of normal structure and elasticity of 
the skin, prevention or treatment of acne, prevention or treatment of cellulitis, ―function of the cell 
membrane‖, ―mucous membranes‖, ―immune system‖, increasing non-specific IgA secretion, 
stimulation of natural killer cell activity, induction of cytokine production, immune defence against 
pathogens, ―essential for the balanced body functions, with special regards to the immune system‖, 
decreasing the absorption of alcohol, increase in muscle creatine stores, and ―improves mechanical 
activity of gallbladder‖. The scientific substantiation is based on the information provided by the 
Member States in the consolidated list of Article 13 health claims and references that EFSA has 
received from Member States or directly from stakeholders. 
 The Panel considers that the following claimed effects are general and non-specific, and do not 
refer to any specific health claims as required by Regulation (EC) No 1924/2006: ―anti-aging 
properties‖ (ID 1352), ―maintenance of urinary tract‖ (ID 1199, 1369), ―cardiovascular health‖ 
(ID 569, 582, 1382), ―vascular and vein health‖ (ID 1480, 1998, 2212, 2753, 3667, 4278), ―blood 
flow/vascular function‖ (ID 1265), ―hormonal balance‖ (ID 1837, 2916), ―women’s health‖ (ID 
531), ―menstrual health‖ (ID 2487), ―absorption of nutrients‖ (ID 1814), ―digestive function‖ (ID 
377, 692, 1267, 1357, 1401, 1625, 2329, 3692), ―gut health‖ (ID 585, 2223), ―intestinal flora‖ (ID 
3076), ―stomach health‖ (ID 2175), ―powerful protectors of the stomach‖ (ID 1368), ―liver 
health‖ (ID 583, 2504), ―nervous system function‖ (ID 1383, 1732) ―mental energy‖ (ID 1530), 
―mental health‖ (ID 555), ―physical and mental health‖ (ID 9), ―physical performance‖ (ID 560, 
4248), ―overtraining and effort prevention‖(ID 4247), ―physical well-being‖ (ID 4407), ―skin 
health‖ (ID 584, 590, 1379, 4241, 4243), ―function of the cell membrane‖ (ID 1777), ―mucous 
membranes‖ (ID 589), ―immune system‖ (ID 675, 847, 1399, 1482, 1792), immune defence 
against pathogens (ID 1477), ―essential for the balanced body functions, with special regards to 
the immune system‖ (ID 675), and ―improves mechanical activity of gallbladder‖ (ID 1342). 
 The Panel considers that the following claimed effects do not refer to a function of the body as 
required by Regulation (EC) No 1924/2006: maintenance of normal structure and appearance of 
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hair and nails structure (ID 1233, 1385, 1746, 1879, 4202), and maintenance of normal structure 
and elasticity of the skin (ID 1385, 1406, 1746, 1879, 1950, 3131). 
 The Panel considers that the following claimed effects are related to the prevention or treatment 
of a disease and do not comply with the criteria laid down in Regulation (EC) No 1924/2006: 
prevention or treatment of prostate cancer (ID 1859, 2773), treatment of diarrhoea and/or 
vomiting (ID 3087), prevention or treatment of acne (ID 2552, 3164), and prevention or treatment 
of cellulitis (ID 2743, 3687). 
 The Panel considers that macronutrient digestion is not impaired in the general population and 
that no evidence has been provided that an improvement of the digestion of macronutrients (e.g. 
carbohydrates, proteins and lipids) (ID 1781, 1842, 2825, 3137, 3519, 3972, 4662, 4691) is a 
beneficial physiological effect per se for the general population. On the basis of the data 
presented, the Panel concludes that a cause and effect relationship has not been established 
between the consumption of the food(s)/food constituent(s) which are the subject of the health 
claims and a beneficial physiological effect related to the digestion of carbohydrates, proteins and 
lipids. 
 The Panel considers that the evidence provided does not establish that increasing numbers of 
gastro-intestinal microorganisms (ID 773, 782, 1399) is a beneficial physiological effect. On the 
basis of the data presented, the Panel concludes that a cause and effect relationship has not been 
established between the consumption of the food(s)/food constituent(s) which are the subject of 
the health claims and a beneficial physiological effect related to increasing numbers of gastro-
intestinal microorganisms. 
 The Panel considers that the evidence provided does not establish that reduction of gastric acid 
(ID 1795, 1906, 2759, 2886) is a beneficial physiological effect per se for the general population. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of the food(s)/food constituent(s) which are the subject 
of the health claims and a beneficial physiological effect related to reduction of gastric acid.  
 The Panel considers that the evidence provided does not establish that increasing non-specific IgA 
secretion (ID 1944) is a beneficial physiological effect per se. On the basis of the data presented, 
the Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the health claims and a 
beneficial physiological effect related to an increase of non-specific IgA secretion. 
 The Panel considers that the evidence provided does not establish that stimulation of natural killer 
cell activity (ID 3128, 3153) is a beneficial physiological effect per se. On the basis of the data 
presented, the Panel concludes that a cause and effect relationship has not been established 
between the consumption of the food(s)/food constituent(s) which are the subject of the health 
claims and a beneficial physiological effect related to the stimulation of natural killer cell activity.  
 The Panel considers that the evidence provided does not establish that induction of cytokine 
production (e.g. TNF-alpha and IFN-gamma) (ID 4112) is a beneficial physiological effect for the 
general population per se. On the basis of the data presented, the Panel concludes that a cause and 
effect relationship has not been established between the consumption of the food(s)/food 
constituent(s) which are the subject of the health claims and a beneficial physiological effect 
related to the induction of cytokine production.  
 The Panel considers that the evidence provided does not establish that decreasing the absorption 
of alcohol (ID 648) is a beneficial physiological effect. On the basis of the data presented, the 
Panel concludes that a cause and effect relationship has not been established between the 
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consumption of the food(s)/food constituent(s) which are the subject of the health claims and a 
beneficial physiological effect related to decreasing the absorption of alcohol. 
 The Panel considers that from the evidence provided the beneficial physiological effect of 
increasing muscle creatine stores is unclear (ID 544, 545). On the basis of the data presented, the 
Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the health claims and a 
beneficial physiological effect related to an increase in muscle creatine stores.  
KEY WORDS 
Food, constituent, not defined, not a function, disease, not beneficial, health claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C.  
ASSESSMENT 
The approach used in the evaluation of Article 13(1) health claims is explained in the general 
guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims
6
.  
In assessing each specific food/health relationship that forms the basis of a health claim the NDA 
Panel considers the extent to which:  
1. the food/constituent is defined and characterised;  
2. the claimed effect is defined and is a beneficial physiological effect (―beneficial to human health‖); 
3. a cause and effect relationship is established between the consumption of the food/constituent and 
the claimed effect (for the target group under the proposed conditions of use).  
Substantiation of the claim is dependent on a favourable outcome of the assessment of 1, 2 and 3 
above. Thus, a cause and effect relationship is considered not to be established if the outcome of any 
one of these assessments is unfavourable.  
For a claim, each relationship between a food/constituent and a claimed effect is assessed separately 
and individual assessments are combined, as appropriate, to form coherent opinions. 
1. Relevance of the claimed effect to human health 
1.1. “Anti-aging properties” (ID 1352) 
The claimed effect is ―anti ageing properties‖. The Panel assumes that the target population is the 
general population.  
The claimed effect is not sufficiently defined and no further details were provided in the proposed 
wordings. No clarifications were provided by Member States. From the references provided it was not 
possible to establish the specific effect which is the target for the claim. 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
6  See footnote 5 
General and non-specific health claims 
 
9 EFSA Journal 2011; 9(6):2228 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006.  
1.2. “Maintenance of urinary tract” (ID 1199, 1369) 
The claimed effects are ―maintenance of urinary tract‖ and ―urinary tract maintenance (Urinary 
Calculus)‖. The Panel assumes that the target population is the general population.  
The claimed effects are not sufficiently defined and no further details were provided in the proposed 
wordings or the clarifications provided by Member States. From the references provided it was not 
possible to establish the specific effect which is the target for the claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006.  
1.3. “Cardiovascular health” (ID 569, 582, 1382) 
The claimed effects are ―cardiovascular system‖ and ―cardiovascular health‖. The Panel assumes that 
the target population is the general population.  
The claimed effects are not sufficiently defined and no further details were provided in the proposed 
wordings or the clarifications provided by Member States. From the references provided it was not 
possible to establish the specific effect which is the target for the claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006.  
1.4. “Vascular and vein health” (ID 1480, 1998, 2212, 2753, 3667, 4278) 
The claimed effects are ―vascular health‖, ―vein health‖, and ―venous system‖. The Panel assumes 
that the target population is the general population. 
The claimed effects are not sufficiently defined. The Panel notes that either different health outcomes 
were mentioned in the references provided, and it was not possible to establish the specific effect 
which is the target of the claim, or that the references provided did not contain original scientific data 
and it was therefore unclear how the health outcomes cited in the proposed wordings (―normal blood 
fluidity and vessel patency‖, ―blood vessel walls strength‖, ―blood circulation‖, ―sensation of heavy 
legs‖, ―good circulation of blood in microvessels‖, ―circulatory well being‖) could be defined and 
assessed.  
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006.  
1.5. “Blood flow/vascular function” (ID 1265) 
The claimed effect is ―blood flow/vascular function‖. The Panel assumes that the target population is 
the general population. 
The claimed effect is not sufficiently defined and no further details were provided in the proposed 
wordings. No clarifications were provided by Member States. The Panel notes that the references 
provided for the substantiation of the claim were either unrelated to the food which is the subject of 
the claim or referred to different health outcomes (i.e. platelet aggregation, endothelial function, 
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oxidative stress) and it was not possible to establish the specific effect which is the target for the 
claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006.  
1.6. “Hormonal balance” (ID 1837, 2916) 
The claimed effects are ―sexual organs and/or hormone activity‖ and ―cell metabolism – positively 
affects the fission of cells their immunity and regeneration‖. The Panel assumes that the target 
population is the general population. 
The claimed effect is not sufficiently defined, and the proposed wordings or the clarifications 
provided by Member States did not provide further information. From the references provided it was 
not possible to establish the specific effect which is the target for the claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006.  
1.7. Prevention or treatment of prostate cancer (ID 1859, 2773) 
The claimed effects are ―sexual organs and/or hormone activity‖ and ―santé de la prostate‖. The Panel 
assumes that the target population is adult males. 
In the context of the proposed wordings or the clarifications provided by Member States, the Panel 
assumes that the claimed effect refers to prostate function. Prostate function is not sufficiently 
defined. From the references provided, the Panel assumes that the claimed effect is related to 
prevention or treatment of prostate cancer. 
The Panel considers that the claimed effect is related to the prevention or treatment of a disease and 
does not comply with the criteria laid down in Regulation (EC) No 1924/2006. 
1.8. “Women’s health” (ID 531) 
The claimed effect is ―women’s health‖. The Panel assumes that the target population is women. 
The claimed effect is not sufficiently defined and no further details were provided in the proposed 
wording or the clarifications provided by Member States. The Panel notes that different health 
outcomes were mentioned in the references provided and it was not possible to establish the specific 
effect which is the target for the claim.  
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006.  
1.9. “Menstrual health” (ID 2487)  
The claimed effect is ―menstrual health‖. The Panel assumes that the target population is women. 
The claimed effect is not sufficiently defined and no further details were provided in the proposed 
wordings. No clarifications were provided by Member States. From the references provided it was not 
possible to establish the specific effect which is the target for the claim. 
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The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006.  
1.10. “Absorption of nutrients” (ID 1814)  
The claimed effect is ―absorption of nutrients‖. The Panel assumes that the target population is the 
general population. 
The claimed effect is not sufficiently defined and from the proposed wordings, the references or the 
clarifications provided by Member States, it was not possible to establish for which nutrients an 
improved absorption is the target for the claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006.  
1.11. Improvement of the digestion of macronutrients (e.g. carbohydrates, proteins and 
lipids) (ID 1781, 1842, 2825, 3137, 3519, 3972, 4662, 4691) 
The claimed effects are ―digestive function‖, ―digestion‖, ―break down of high-molecules compound 
from food‖, ―pancreas‖ and ―digestive system benefits‖. The Panel assumes that the target population 
is the general population.  
In the context of the proposed wordings and clarifications provided by Member States, the Panel 
assumes that the claimed effects refer to the facilitation of the digestion of macronutrients (e.g. 
dietary carbohydrates, proteins and lipids) in the gastro-intestinal tract.  
The human gastro-intestinal tract capacity for digestion of macronutrients is very high and it is 
estimated that in physiological situation it exceeds tenfold the biological demand. The Panel considers 
that macronutrient digestion is not impaired in the general population and that no evidence has been 
provided that an improvement of the digestion of macronutrients (e.g. carbohydrates, proteins and 
lipids) is a beneficial physiological effect per se for the general population. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the health claims and a 
beneficial physiological effect related to the digestion of carbohydrates, proteins and lipids. 
1.12. “Digestive function” (ID 377, 692, 1267, 1357, 1401, 1625, 2329, 3692) 
The claimed effects are ―joue un rôle dans le processus digestif‖, ―essential fatty acids to aid in 
digestive tract function‖, ―consumption of bran improves digestive function‖, ―naturally boost your 
digestive system‖, ―digestion (stimulation)‖, ―gastro-intestinal support‖ and ―digestion‖. The Panel 
assumes that the target population is the general population. 
The claimed effects are not sufficiently defined and no further details were available in the proposed 
wordings, the references or the clarifications provided by Member States.  
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
1.13. “Gut health” (ID 585, 2223) 
The claimed effects are ―gut health‖ and ―intestinal health‖. The Panel assumes that the target 
population is the general population. 
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The claimed effects are not sufficiently defined and no further details were provided in the proposed 
wordings. No clarifications were provided by Member States. From the references provided it was not 
possible to establish the specific effect which is the target for the claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
1.14. “Intestinal flora” (ID 3076) 
The claimed effect is ―intestinal flora‖. The Panel assumes that the target population is the general 
population. 
The claimed effect is not sufficiently defined and no further details were provided in the proposed 
wordings. The Panel notes that different health outcomes were mentioned in the references provided 
and it was not possible to establish the specific effect which is the target for the claim.  
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
1.15. Increasing numbers of gastro-intestinal microorganisms (ID 773, 782, 1399) 
The claimed effects are ―increased inner protection/resistance‖, ―prebiotic/bifidogenic‖, and ―benefits 
the growth of intestinal bifidus bacteria and stimulates the immune system‖. The Panel assumes that 
the target population is the general population. 
In the context of the proposed wordings or the clarifications provided by Member States, the Panel 
assumes that the claimed effects refer to an increase in the number of bacteria that are considered to 
be beneficial. 
The numbers/proportions of bacterial groups that would constitute a ―good, balanced, healthy or 
beneficial intestinal flora‖ have not been established. Increasing the number of any group of 
microorganisms including lactobacilli or bifidobacteria, is not in itself considered to be a beneficial 
physiological effect.  
The Panel considers that the evidence provided does not establish that increasing numbers of 
gastro-intestinal microorganisms is a beneficial physiological effect. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the health claims and a 
beneficial physiological effect related to increasing numbers of gastro-intestinal microorganisms. 
1.16. “Stomach health” (ID 2175) 
The claimed effect is ―stomach health‖. The Panel assumes that the target population is the general 
population. 
The claimed effect is not sufficiently defined and no further details were provided in the proposed 
wordings. No clarifications were provided by Member States. From the references provided it was not 
possible to establish the specific effect which is the target for the claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
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1.17. “Powerful protectors of the stomach” (ID 1368) 
The claimed effect is ―more recently, emerging research suggests that cranberries may also be 
powerful protectors of the stomach‖. The Panel assumes that the target population is the general 
population. 
The claimed effect is not sufficiently defined and no further details were provided in the proposed 
wording. No clarifications were provided by Member States. From the references provided it was not 
possible to establish the specific effect which is the target for the claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
1.18. Reduction of gastric acid (ID 1795, 1906, 2759, 2886) 
The claimed effects are ―gut health‖, ―gastrointestinal health‖, ―gastric acidity‖ and ―stomach acid in 
digestion‖. The Panel assumes that the target population is the general population. 
For ID 1795, 2759, 2886, in the context of the proposed wordings, the Panel assumes that the claimed 
effect refers to the reduction of gastric acid. 
For ID 1906, in the context of the proposed wording, the clarifications provided by Member States, 
and the references cited for the scientific substantiation of the claim, the Panel assumes that the 
claimed effect refers to the protection of the mucous membrane of the stomach by reducing gastric 
acid. 
The Panel considers that the evidence provided does not establish that reducing gastric acid is a 
beneficial physiological effect per se for the general population. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the health claims and a 
beneficial physiological effect related to reduction of gastric acid.  
1.19. Treatment of diarrhoea and/or vomiting (ID 3087)  
The claimed effect is ―ORSALIT is given in order to supplement liquids and mineral components 
during diarrhoea and/or vomiting‖. The Panel assumes that the target population is individuals who 
are suffering from diarrhoea and/or vomiting.  
The Panel assumes that the claimed effect is related to treatment of a disease (diarrhoea and/or 
vomiting). 
The Panel considers that the claimed effect is related to the treatment of a disease and does not 
comply with the criteria laid down in Regulation (EC) No 1924/2006. 
1.20. “Liver health” (ID 583, 2504) 
The claimed effects are ―liver‖ and ―liver health‖. The Panel assumes that the target population is the 
general population. 
The claimed effects are not sufficiently defined and no further details were provided in the proposed 
wording. No clarifications were provided by Member States. From the references provided it was not 
possible to establish the specific effect which is the target for the claim. 
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The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
1.21. “Nervous system function” (ID 1383, 1732) 
The claimed effect is ―nervous system function‖. The Panel assumes that the target population is the 
general population. 
The claimed effect is not sufficiently defined and no further details were provided in the proposed 
wordings. No clarifications were provided by Member States. From the references provided it was not 
possible to establish the specific effect which is the target for the claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
1.22. “Mental energy” (ID 1530) 
The claimed effect is ―for mental energy‖. The Panel assumes that the target population is the general 
population. 
The claimed effect is not sufficiently defined and no further details were provided in the proposed 
wordings. No clarifications were provided by Member States. From the reference provided it was not 
possible to establish the specific effect which is the target for the claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006.  
1.23. “Mental health” (ID 555) 
The claimed effect is ―mental health‖. The Panel assumes that the target population is the general 
population.  
The claimed effect is not sufficiently defined and no further details were provided in the proposed 
wordings. No clarifications were provided by Member States. From the reference provided it was not 
possible to establish the specific effect which is the target for the claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006.  
1.24. “Physical and mental health” (ID 9) 
The claimed effect is ―physical and mental health‖. The Panel assumes that the target population is 
the general population.  
The claimed effect is not sufficiently defined and no further details were available in the proposed 
wordings. The Panel notes that different health outcomes were mentioned in the clarifications 
provided by Member States or the references provided and it was not possible to establish the specific 
effect which is the target for the claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
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1.25. “Physical performance” (ID 560, 4248) 
The claimed effects are ―physical performance and condition‖ and ―physical performance‖. The Panel 
assumes that the target population is the general population. 
The claimed effects are not sufficiently defined and no further details were provided in the proposed 
wordings. No clarifications were provided by Member States. From the references provided it was not 
possible to establish the specific effect which is the target for the claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
1.26. “Overtraining and effort prevention” (ID 4247) 
The claimed effect is ―overtraining and effort prevention‖. The Panel assumes that the target 
population is the general population.  
The claimed effect is not sufficiently defined and no further details were provided in the proposed 
wordings. No clarifications were provided by Member States. From the references provided it was not 
possible to establish the specific effect which is the target for the claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
1.27. “Physical well-being” (ID 4407) 
The claimed effect is ―physical well-being‖. The Panel assumes that the target population is the 
general population. 
The claimed effect is not sufficiently defined and no further details were provided in the proposed 
wording. From the reference provided it was not possible to establish the specific effect which is the 
target for the claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
1.28. “Skin health” (ID 584, 590, 1379, 4241, 4243)  
The claimed effects are ―skin‖, ―skin health‖ and ―skin care‖. The Panel assumes that the target 
population is the general population. 
The claimed effects are not sufficiently defined and no further details were provided in the proposed 
wordings. No clarifications were provided by Member States. From the references provided it was not 
possible to establish the specific effect which is the target for the claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
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1.29. Maintenance of normal structure and appearance of hair and nails (ID 1233, 1385, 
 1746, 1879, 4202) 
The claimed effects are ―hair and nails health‖, ―skin health‖, ―essential part of the connective tissues, 
skin and hair‖, ―hair beauty and health‖, ―healthy hair, skin and nails‖ and ―hair beauty and health‖. 
The Panel assumes that the target population is the general population. 
In the context of the proposed wordings or the clarifications provided by Member States, the Panel 
assumes that the claimed effects refer to the maintenance of normal structure and appearance of hair 
and nails.  
The Panel considers that the claimed effects do not refer to a function of the body as required by 
Regulation (EC) No 1924/2006. 
1.30. Maintenance of normal structure and elasticity of the skin (ID 1385, 1406, 1746, 1879, 
1950, 3131) 
The claimed effects are ―skin health‖, ―skin health, in particular skin surface: significant reduction of 
skin density‖, ―essential part of the connective tissues, skin and hair‖, ―healthy hair, skin and nails‖ 
and ―helps to keep elasticity of skin‖. The Panel assumes that the target population is the general 
population. 
In the context of the proposed wordings or the clarification provided by Member States, the Panel 
assumes that the claimed effects refer to the maintenance of the normal structure and elasticity of the 
skin. The references provided did not refer to a particular physiological function of the skin. 
The Panel considers that the claimed effects do not refer to a function of the body as required by 
Regulation (EC) No 1924/2006. 
1.31. Prevention or treatment of acne (ID 2552, 3164) 
The claimed effects are ―epiderme, soigne l'acnée‖ and ―skin health‖. The Panel assumes that the 
target population is the general population. 
In the context of the clarifications provided, the Panel considers that the claimed effects refer to the 
prevention or treatment of acne, which is a skin disease, characterised by pimples on the face, chest, 
and back and occurs when the pores of the skin become clogged with oil, dead skin cells, and bacteria.  
The Panel considers that the claimed effect is related to the prevention or treatment of a disease and 
does not comply with the criteria laid down in Regulation (EC) No 1924/2006. 
1.32. Prevention or treatment of cellulitis (ID 2743, 3687) 
The claimed effect is ―skin curves/cellulitis‖. The Panel assumes that the target population is the 
general population. 
The Panel assumes that the claimed effect is related to the treatment of cellulitis, which is a common 
skin infection caused by bacteria, most commonly caused by Streptococcus pyogenes or 
Staphylococcus aureus. 
The Panel considers that the claimed effect is related to the prevention or treatment of a disease and 
does not comply with the criteria laid down in Regulation (EC) No 1924/2006. 
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1.33. “Function of the cell membrane” (ID 1777) 
The claimed effect is ―function of the cell membrane‖. The Panel assumes that the target population is 
the general population.  
The claimed effect is not sufficiently defined. Cell membranes may have different structures and 
functions depending on their composition and the cell type they belong to. The Panel notes that 
several properties of cell membranes were mentioned in the proposed wordings and that a specific 
effect related to the function of cell membranes has not been identified. No further clarifications were 
provided by Member States. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006.  
1.34. “Mucous membranes” (ID 589) 
The claimed effect is ―mucous membranes‖. The Panel assumes that the target population is the 
general population.  
The claimed effect is not sufficiently defined. Mucosa is the inner lining tissue of organs e.g. 
digestive, respiratory and urogenital tracts and the inner surface of the eyes. It acts as protective layer 
against different environmental detrimental factors. The Panel notes that several mucous membranes 
were mentioned in the clarifications provided by Member States and that a specific effect related to 
the function of mucous membranes has not been identified.  
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006.  
1.35. “Immune system” (ID 675, 847, 1399, 1482, 1792) 
The claimed effects are ―essential for the balanced body functions, with special regards to the immune 
system‖, ―immune health‖, ―stimulation of the immune system‖, ―immune system function‖ and 
―immunity‖. The Panel assumes that the target population is the general population. 
The claimed effect is not sufficiently defined and no further details were available in the proposed 
wording or the clarifications provided by Member States. Given the multiple roles of the immune 
system, the specific aspect of immune function, which is the subject of the health claim, needs to be 
specified but has not been indicated in the information provided.  
The Panel considers that the claimed effects are general and non-specific, and do not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
1.36. Increase of non-specific IgA secretion (ID 1944) 
The claimed effect is ―immune health‖. The Panel assumes that the target population is the general 
population.  
In the context of the clarifications provided by the Member States, the Panel assumes that the claimed 
effect refers to ―promotes a healthy immune system by notably increasing IgA‖.  
The Panel considers that the evidence provided does not establish that increasing non-specific IgA 
secretion is a beneficial physiological effect per se. 
General and non-specific health claims 
 
18 EFSA Journal 2011; 9(6):2228 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the health claim and a 
beneficial physiological effect related to an increase of non-specific IgA secretion. 
1.37. Stimulation of natural killer cell activity (ID 3128, 3153) 
The claimed effects are ―immune system‖ and ―strengthens immune systems‖. The Panel assumes that 
the target population is the general population.  
In the context of the clarifications provided by Member States, the Panel assumes that the claimed 
effect refers to the stimulation of natural killer cell activity.  
The Panel considers that the evidence provided does not establish that stimulation of natural killer cell 
activity is a beneficial physiological effect per se.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the health claims and a 
beneficial physiological effect related to the stimulation of natural killer cell activity.  
1.38. Induction of cytokine production (ID 4112) 
The claimed effect is ―immune support‖. The Panel assumes that the target population is the general 
population. 
In the context of the clarifications provided by Member States, the Panel assumes that the claimed 
effect refers to supporting immune health by inducing cytokine production (e.g. TNF-alpha and 
IFN-gamma).  
The Panel considers that the evidence provided does not establish that induction of cytokine 
production (e.g. TNF-alpha and IFN-gamma) is a beneficial physiological effect for the general 
population per se.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the health claims and a 
beneficial physiological effect related to the induction of cytokine production.  
1.39. Immune defence against pathogens (ID 1477) 
The claimed effect is ―antimicrobial/antiviral/innate host defense‖. The Panel assumes that the target 
population is the general population.  
In the context of the clarifications provided by Member States, the Panel assumes that the claimed 
effect refers to immune defence against pathogens.  
The Panel notes that the type of infection has not been specified and the references provided 
addressed several effects (e.g. related to treatment of tinea pedis (athletes foot), eradication of 
Helicobacter pylori, lower respiratory tract illnesses, the effects of long-term administration of bovine 
lactoferrin in patients with chronic hepatitis C, effects in post-surgical patients) and it was not 
possible to establish which of these effects is the target for the claim. 
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006.  
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1.40. “Essential for the balanced body functions, with special regards to the immune system” 
(ID 675) 
The claimed effect is ―essential for the balanced body functions, with special regards to the immune 
system‖. The Panel assumes that the target population is the general population. 
The claimed effect is not sufficiently defined and no further details were available in the proposed 
wordings. The clarifications provided by Member States included several physiological functions and 
the references provided did not allow the identification of the specific function which is the target for 
the claim.  
The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006. 
1.41. Decreasing the absorption of alcohol (ID 648) 
The claimed effect is ―slows the absorption of alcohol‖. The Panel assumes that the target population 
is the general population. 
In the context of the clarifications provided by Member States, the Panel assumes that the claimed 
effect refers to decreasing the absorption of alcohol. 
The Panel considers that the evidence provided does not establish that decreasing the absorption of 
alcohol is a beneficial physiological effect. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the health claims and a 
beneficial physiological effect related to decreasing the absorption of alcohol. 
1.42. Increase in muscle creatine stores (ID 544, 545) 
The claimed effects are ―increased muscle creatine storage‖ and ―enhancing storage & uptake‖. The 
Panel assumes that the target population is active individuals in the general population. 
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to an 
increase in muscle creatine stores. 
The Panel notes that from the references provided the beneficial physiological effect of increasing 
muscle creatine stores is unclear.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the health claims and a 
beneficial physiological effect related to an increase in muscle creatine stores.  
1.43. “Improves mechanical activity of gallbladder” (ID 1342) 
The claimed effect is ―improves mechanical activity of gallbladder‖. The Panel assumes that the 
target population is the general population. 
The claimed effect is not sufficiently defined and no further details were available in the proposed 
wordings. The Panel notes that is unclear whether the claim refers to an increase or to a decrease in 
the frequency or the intensity of contraction of the gallbladder wall, and none of the references 
provided refers to the function of the gallbladder.  
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The Panel considers that the claimed effect is general and non-specific, and does not refer to any 
specific health claim as required by Regulation (EC) No 1924/2006.  
CONCLUSIONS  
On the basis of the data presented the Panel concludes that: 
 The claimed effects: ―anti-aging properties‖ (ID 1352), ―maintenance of urinary tract‖ 
(ID 1199, 1369), ―cardiovascular health‖ (ID 569, 582, 1382), ―vascular and vein health‖ (ID 
1480, 1998, 2212, 2753, 3667, 4278), ―blood flow/vascular function‖ (ID 1265), ―hormonal 
balance‖ (ID 1837, 2916), ―women’s health‖ (ID 531), ―menstrual health‖ (ID 2487), 
―absorption of nutrients‖ (ID 1814), ―digestive function‖ (ID 377, 692, 1267, 1357, 1401, 
1625, 2329, 3692), ―gut health‖ (ID 585, 2223), ―intestinal flora‖ (ID 3076), ―stomach health‖ 
(ID 2175), ―powerful protectors of the stomach‖ (ID 1368), ―liver health‖ (ID 583, 2504), 
―nervous system function‖ (ID 1383, 1732) ―mental energy‖ (ID 1530), ―mental health‖ (ID 
555), ―physical and mental health‖ (ID 9), ―physical performance‖ (ID 560, 4248), 
―overtraining and effort prevention‖(ID 4247), ―physical well-being‖ (ID 4407), ―skin health‖ 
(ID 584, 590, 1379, 4241, 4243), ―function of the cell membrane‖ (ID 1777), ―mucous 
membranes‖ (ID 589), ―immune system‖ (ID 675, 847, 1399, 1482, 1792), immune defence 
against pathogens (ID 1477), ―essential for the balanced body functions, with special regards 
to the immune system‖ (ID 675), and ―improves mechanical activity of gallbladder‖ (ID 
1342), are general and non-specific, and do not refer to any specific health claims as required 
by Regulation (EC) No 1924/2006. 
 The claimed effects are ―hair and nails health‖, ―skin health‖, ―essential part of the connective 
tissues, skin and hair‖, ―hair beauty and health‖, ―healthy hair, skin and nails‖; ―skin health‖, 
―skin health, in particular skin surface: significant reduction of skin density‖, ―essential part of 
the connective tissues, skin and hair‖, ―healthy hair, skin and nails‖ and ―helps to keep elasticity 
of skin‖. Maintenance of the normal structure and elasticity of the skin (ID 1233, 1385, 1746, 
1879, 4202), and maintenance of normal structure and elasticity of the skin (ID 1385, 1406, 1746, 
1879, 1950, 3131), do not refer to a function of the body as required by Regulation (EC) No 
1924/2006. 
 The claimed effects are ―sexual organs and/or hormone activity‖, ―santé de la prostate‖; 
―ORSALIT is given in order to supplement liquids and mineral components during diarrhoea 
and/or vomiting‖; ―epiderme, soigne l'acnée‖, ―skin health‖; and ―skin curves/cellulitis‖. 
Prevention or treatment of prostate cancer (ID 1859, 2773), treatment of diarrhoea and/or 
vomiting (ID 3087), prevention or treatment of acne (ID 2552, 3164), and prevention or 
treatment of cellulitis (ID 2743, 3687), are related to the prevention or treatment of a disease 
and do not comply with the criteria laid down in Regulation (EC) No 1924/2006. 
 The claimed effects are ―digestive function‖, ―digestion‖, ―break down of high-molecules 
compound from food‖, ―pancreas‖ and ―digestive system benefits‖. Macronutrient digestion is not 
impaired in the general population and no evidence has been provided that an improvement of the 
digestion of macronutrients (e.g. carbohydrates, proteins and lipids) (ID 1781, 1842, 2825, 3137, 
3519, 3972, 4662, 4691) is a beneficial physiological effect per se  for the general population. A 
cause and effect relationship has not been established between the consumption of the 
food(s)/food constituent(s) which are the subject of the health claims and a beneficial 
physiological effect related to the digestion of carbohydrates, proteins and lipids. 
 The claimed effects are ―increased inner protection/resistance‖, ―prebiotic/bifidogenic‖, and 
―benefits the growth of intestinal bifidus bacteria and stimulates the immune system‖. The 
evidence provided does not establish that increasing numbers of gastro-intestinal microorganisms 
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(ID 773, 782, 1399) is a beneficial physiological effect. A cause and effect relationship has not 
been established between the consumption of the food(s)/food constituent(s) which are the subject 
of the health claims and a beneficial physiological effect related to increasing numbers of gastro-
intestinal microorganisms. 
 The claimed effects are ―gut health‖, ―gastric acidity‖ and ―stomach acid in digestion‖. The 
evidence provided does not establish that reduction of gastric acid (ID 1795, 1906, 2759, 2886) is 
a beneficial physiological effect per se for the general population. A cause and effect relationship 
has not been established between the consumption of the food(s)/food constituent(s) which are the 
subject of the health claims and a beneficial physiological effect related to reduction of gastric 
acid.  
 The claimed effect is ―immune health‖. The evidence provided does not establish that increasing 
non-specific IgA secretion (ID 1944) is a beneficial physiological effect per se. A cause and effect 
relationship has not been established between the consumption of the food(s)/food constituent(s) 
which are the subject of the health claims and a beneficial physiological effect related to an 
increase of non-specific IgA secretion. 
 The claimed effects are ―immune system‖ and ―strengthens immune systems‖. The evidence 
provided does not establish that stimulation of natural killer cell activity (ID 3128, 3153) is a 
beneficial physiological effect per se. A cause and effect relationship has not been established 
between the consumption of the food(s)/food constituent(s) which are the subject of the health 
claims and a beneficial physiological effect related to the stimulation of natural killer cell activity.  
 The claimed effect is ―immune support‖. The evidence provided does not establish that induction 
of cytokine production (e.g. TNF-alpha and IFN-gamma) (ID 4112) is a beneficial physiological 
effect per se for the general population. A cause and effect relationship has not been established 
between the consumption of the food(s)/food constituent(s) which are the subject of the health 
claims and a beneficial physiological effect related to the induction of cytokine production.  
 The claimed effect is ―slows the absorption of alcohol‖. The evidence provided does not establish 
that decreasing the absorption of alcohol (ID 648) is a beneficial physiological effect. A cause and 
effect relationship has not been established between the consumption of the food(s)/food 
constituent(s) which are the subject of the health claims and a beneficial physiological effect 
related to decreasing the absorption of alcohol. 
 The claimed effects are ―increased muscle creatine storage‖ and ―enhancing storage & uptake‖. 
From the evidence provided the beneficial physiological effect of increasing muscle creatine 
stores is unclear (ID 544, 545). A cause and effect relationship has not been established between 
the consumption of the food(s)/food constituent(s) which are the subject of the health claims and 
a beneficial physiological effect related to an increase in muscle creatine stores.  
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-796, 
EFSA-Q-2008-1164, EFSA-Q-2008-1318, EFSA-Q-2008-1331, EFSA-Q-2008-1332, EFSA-Q-2008-
1342, EFSA-Q-2008-1347, EFSA-Q-2008-1356, EFSA-Q-2008-1369, EFSA-Q-2008-1370, EFSA-Q-
2008-1371, EFSA-Q-2008-1372, EFSA-Q-2008-1376, EFSA-Q-2008-1377, EFSA-Q-2008-1435, 
EFSA-Q-2008-1462, EFSA-Q-2008-1479, EFSA-Q-2008-1560, EFSA-Q-2008-1569, EFSA-Q-2008-
1634, EFSA-Q-2008-1938, EFSA-Q-2008-1971, EFSA-Q-2008-2003, EFSA-Q-2008-2005, EFSA-Q-
2008-2079, EFSA-Q-2008-2089, EFSA-Q-2008-2094, EFSA-Q-2008-2105, EFSA-Q-2008-2106, 
EFSA-Q-2008-2116, EFSA-Q-2008-2119, EFSA-Q-2008-2120, EFSA-Q-2008-2122, EFSA-Q-2008-
2136, EFSA-Q-2008-2138, EFSA-Q-2008-2143, EFSA-Q-2008-2214, EFSA-Q-2008-2217, EFSA-Q-
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2008-2219, EFSA-Q-2008-2267, EFSA-Q-2008-2361, EFSA-Q-2008-2468, EFSA-Q-2008-2479, 
EFSA-Q-2008-2510, EFSA-Q-2008-2514, EFSA-Q-2008-2525, EFSA-Q-2008-2528, EFSA-Q-2008-
2547, EFSA-Q-2008-2570, EFSA-Q-2008-2575, EFSA-Q-2008-2592, EFSA-Q-2008-2612, EFSA-Q-
2008-2639, EFSA-Q-2008-2677, EFSA-Q-2008-2683, EFSA-Q-2008-2731, EFSA-Q-2008-2908, 
EFSA-Q-2008-2945, EFSA-Q-2008-2956, EFSA-Q-2008-3062, EFSA-Q-2008-3220, EFSA-Q-2008-
3237, EFSA-Q-2008-3285, EFSA-Q-2008-3476, EFSA-Q-2008-3486, EFSA-Q-2008-3492, EFSA-Q-
2008-3506, EFSA-Q-2008-3558, EFSA-Q-2008-3619, EFSA-Q-2008-3649, EFSA-Q-2008-3808, 
EFSA-Q-2008-3819, EFSA-Q-2008-3860, EFSA-Q-2008-3863, EFSA-Q-2008-3869, EFSA-Q-2008-
3885, EFSA-Q-2008-3896, EFSA-Q-2008-4246, EFSA-Q-2008-4390, EFSA-Q-2008-4410, EFSA-Q-
2008-4415, EFSA-Q-2008-4687, EFSA-Q-2008-4823, EFSA-Q-2008-4912, EFSA-Q-2008-4951, 
EFSA-Q-2008-4953, EFSA-Q-2008-4957, EFSA-Q-2008-4958, EFSA-Q-2010-00231, EFSA-Q-2010-
00360, EFSA-Q-2010-00615, EFSA-Q-2010-00644). The scientific substantiation is based on the 
information provided by the Member States in the consolidated list of Article 13 health claims and 
references that EFSA has received from Member States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
7
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health". 
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be: 
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3). 
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
8
  
Foods are commonly involved in many different functions
9
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent. 
                                                     
7 OJ L12, 18/01/2007 
8 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
9 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect. 
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects: 
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent. 
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
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consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to various food(s)/food constituent(s) claiming general and 
non-specific health effects, including conditions of use from similar claims, as proposed in the 
Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
9 Vitamins, minerals, trace 
elements and standardized 
ginseng G115 extract 
(Pharmaton Activit G 
effervescent tablets). 
 
Physical and mental 
health. 
Clarification provided 
Vitamins, minerals, trace 
elements and 
standardised ginseng 
G115 extract are 
scientifically proven to 
maintain energy within 
the body and to help 
coping with daily stress 
symptoms such as 
tiredness, fatigue, body 
weakness, decreased 
concentration and 
decreased alertness, by: 
- enhancing oxygen 
uptake in body cells 
- reducing the lactate 
level in body tissues 
- enhancing the 
reoxygenation of 
haemoglobin in the blood 
circulation system. 
OR 
Vitamins, minerals and 
trace elements support 
the metabolism to release 
energy from 
carbohydrates, proteins 
and fats. 
Supports mental 
functions (especially in 
the elderly) and help the 
brain and nerves to work 
properly. 
Scientifically proven: Helps to 
sustain energy, performance and 
concentration throughout the day. 
Scientifically proven: Helps to 
maintain mental and physical 
performance. 
Conditions of use 
- 600 - 650 g / Tag. 
- Applicable to multivitamin/mineral product which contains following daily dosage: Beta-
carotene 2mg, Vitamin D 5mcg, Vitamin E 10mg, Vitamin C 60mg, Vitamin B1 1.4mg, 
Vitamin B2 1.6mg, Niacin 18mg, Vitamin B6 2mg, Folic acid 200mcg, Vitamin B12 1mcg, 
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Biotin 150mcg, Calcium 100mg, Iron 10mg, Magnesium 40mg, Zinc 1mg, Copper 1.1mg, 
Selenium 50mcg, Panax Ginseng extract G115 40mg. 
ID Food or Food constituent Health Relationship Proposed wording 
377 Bicarbonate Joue un rôle dans le 
processus digestif 
Pendant les repas, elle (NB : l'eau 
minérale naturelle DIDIER) facilite 
la digestion grâce à sa teneur en 
bicarbonate - Le bicarbonate permet 
une meilleure digestion et aide à 
lutter contre les maux d'estomac 
Conditions of use 
- Article 1321-78 du Code de la Santé Publique. Composition minérale moyenne DIDIER 
(mg/l) : Bicarbonate (1280) 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
531 Omega-3 and Omega-6 
fatty acids (GLA) 
Women´s health 
Clarification provided 
Omega-3 Fatty acids help 
improve women’s 
emotional and mental 
wellbeing 
Omega-3 fatty acids with GLA 
support women during menstruation, 
PMS and menopause 
Conditions of use 
- 400 – 1000mg DHA + EPA 1-3g EPO per day corresponds to 90-330mg GLA per day 
Comments from Member States 
Please change "Food category" to "Omega-3 Fatty Acids" 
ID Food or Food constituent Health Relationship Proposed wording 
544 Creatine and carbohydrate 
Clarification provided 
Creatine and carbohydrate 
in sports nutrition : 
products 
Claim to be only used for 
Foods for sportpeople 
under the Dir. 89/398/EEC.  
Sports foods and food 
supplements providing at 
least 0.07g creatine per kg 
body mass and at least 
0.26g carbohydrate per kg 
body mass, per serve  
OR 
Sports foods and food 
supplements providing at 
least 5g creatine and 18g 
Increased muscle creatine 
storage 
Combined creatine and carbohydrate 
increases muscle creatine stores 
compared to creatine alone. 
Helps deliver creatine to the muscle 
effectively. 
Creatine retention is increased when 
consumed with carbohydrate. 
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carbohydrate per serve 
Conditions of use 
- Claim to be only used for Foods for sportpeople under the Dir. 89/398/EEC. Sports foods 
and food supplements providing 0.08 g/kg body weight per recommended daily 
consumption.  
0.8g creatine /kg body weight 
ID Food or Food constituent Health Relationship Proposed wording 
545 Creatine plus Carbohydrate 
(dextrose, sugar) 
Clarification provided 
Creatine plus Carbohydrate 
(dextrose, sugar) 
Food or food supplement 
must contain at least 1 
gram Creatine and 30 g 
Dextrose per serving 
Enhancing Storage & 
Uptake 
Blend of ingredients clinically shown 
to help enhance creatine uptake into 
muscle 
University tests show that a blend of 
creatine and high-glycemic 
carbohydrate promotes creatine 
uptake and storage in muscle tissue 
Conditions of use 
- The product must contain at least 1 gram creatine and 30 g dextrose per serving Claim to be 
used for foods for active individuals 
ID Food or Food constituent Health Relationship Proposed wording 
555 Fructose Mental health Improves well-being after alcohol use 
Conditions of use 
- 250 ml 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
569 Berry seed oils 
(supercritical carbon 
dioxide extract). 
Cardiovascular system. 
Clarification provided 
Berry seed oils are rich 
sources of omega-3 
alpha-linolenic acid. The 
omega-3 fatty acids in 
berry seed oils improve 
the balance of omega-3 ja 
omega-6 in the body. Due 
to the favourable profile 
of essential fatty acids, 
berry seed oils support 
cardiovascular health. 
The essential fatty acids in berry seed 
oils balance fatty acid metabolism in 
the body. 
Berry seed oils support the health of 
the cardiovascular system. 
Conditions of use 
- Seed oils from wild berries such as lingonberry, bilberry and cranberry and from domestic 
berries such as strawberry and raspberry and sea buckthorn berry oils. The amount was not 
indicated. 
The seed oils are produced by means of supercritical carbon dioxide extraction. 
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ID Food or Food constituent Health Relationship Proposed wording 
582 Sea buckthorn berry oil 
(cold-pressed). 
Cardiovascular system. Healthy for the heart and blood 
vessels. 
Conditions of use 
- Food supplement with 2 g of cold-pressed sea buckthorn berry oil (pulp oil) in the daily 
dose. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
583 Sea buckthorn berry oil 
(cold-pressed). 
Liver. Protects the liver. 
Conditions of use 
- Food supplement with 2 g of cold-pressed sea buckthorn berry oil (pulp oil) in the daily 
dose. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
584 Sea buckthorn berry oil 
(cold-pressed). 
Skin. Healthy for the skin and mucous 
membranes. 
Conditions of use 
- Food supplement with 2 g of cold-pressed sea buckthorn berry oil (pulp oil) in the daily 
dose. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
585 Sea buckthorn berry oil 
(cold-pressed). 
Gut health. Healthy for the stomach. 
Protects the gut. 
Conditions of use 
- Food supplement with 2 g of cold-pressed sea buckthorn berry oil (pulp oil) in the daily 
dose. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
589 Sea buckthorn seed oil and 
pulp oil 
Mucous membranes 
Clarification provided 
Standardised sea 
buckthorn oil SBA24 
manufactured by 
supercritical CO2 
maintains the health of 
female genital mucosa 
especially in females of 
post-menopausal age. 
Standardised sea 
buckthorn oil SBA24 
manufactured by 
Sea buckthorn seed and pulp oil 
nourish the mucous membranes and 
help to maintain their normal 
structure and functioning. 
Sea buckthorn seed and pulp oil 
moisturise dry mucous membranes. 
Sea buckthorn seed and pulp oil 
strengthen and protect the mucous 
membranes of the stomach. 
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supercritical CO2 
maintains the health of 
gastric mucosa, the 
mucous membranes of 
the stomach. 
Standardised sea 
buckthorn oil SBA24 
manufactured by 
supercritical CO2 
maintains the health of 
mucosa of eyes and 
mouth 
Conditions of use 
- Food supplement that has 1000-2000 mg of sea buckthorn seed and pulp oil in the daily 
dose. 
Comments from Member States 
Health relationship defined  
ID Food or Food constituent Health Relationship Proposed wording 
590 Sea buckthorn oil. Skin. For skin health / well-being. 
Conditions of use 
- Serving required for the effect: In clinical studies beneficial effects have been achieved by 
using 5 g of sea buckthorn seed oil or sea buckthorn seed oil produced by supercritical 
extraction. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
648 Mix of Glucose-Fructose slows the absorbtion of 
alcohol 
Clarification provided 
increases blood flow and 
alcohol elimination in the 
liver 
 
helps to lower level of the consumed 
alcohol in the body by decelerating of 
the absorbin of alcohol 
Conditions of use 
- at least 6g of Glucose and Fructose / not recommended for diabetics 
ID Food or Food constituent Health Relationship Proposed wording 
675 Polyunsatu-rated fatty 
acids: n-3/n-6 (omega 3 / 
omega 6) ratio 
Optimal linolenic / 
linoleic acid ratio is 
essential for the balanced 
body functions, with 
special regards to the 
immune system. 
Clarification provided 
Optimal linolenic / 
linoleic acid ratio is 
Optimal (1/5-1/8) linolenic / linoleic 
acid (n-3 / n-6) ratio in the diet is 
essential for the good balanced 
function of the body and the immune 
system.;DHA and EPA are formed 
from these two essential fatty acids. 
Transformation is mediated by the 
same enzymes; therefore adequate 
precursor ratio (n-3 / n-6 = 1/5 - 1/8) 
is important for balanced DHA/EPA 
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essential for the good 
balanced body functions, 
with special regards to 
the nervous tissue, skin, 
retina and the immune 
system. 
Clarification:'DHA is a 
component of membrane 
structural lipids, 
especially in nervous 
tissue and the retina. EPA 
is the precursor for series 
3 prostanoids and series 5 
leukotrienes, which 
participate in the 
regulation of blood 
pressure, renal function, 
blood coagulation, 
inflammatory and 
immunological 
reactions.Because of he 
competition for metabolic 
enzymes between the 
fatty acids of n-6 and n-3 
series, it is important to 
maintain a balance 
between n-6 and n-3 
PUFA in the diet. 
synthesis.; 
Conditions of use 
- 1/5 – 1/8 (linolenic / linoleic acid) ratio in the daily diet or in the food.;The product shall 
comply with the conditions of nutrition claim „High polyunsaturated fat‖.;; 
ID Food or Food constituent Health Relationship Proposed wording 
692 Essential Fatty Acids Essential fatty acids to 
aid in digestive tract 
function. 
Essential fatty acids to aid in 
digestive tract function. 
Conditions of use 
- No RDA / RNI. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
773 Chicory oligofructose Increased inner 
protection/ resistance 
Clarification provided 
Increased inner 
protection/ resistance. 
Improved intestinal 
function/ digestive health 
and increased inner 
protection/ resistance. 
Increases number of 
contributes to your body's natural 
defences; 
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beneficial bacteria in the 
gut. 
Conditions of use 
- 5 bis 9 Gramm (g) 
- 12 g/Tag. beginnt bei 12g/Tag 
- Where a daily value is indicated the amount per serving is typicaly 25% unless otherwise 
stated. 12g/day 
- beginnt bei 12g pro Tag 
ID Food or Food constituent Health Relationship Proposed wording 
782 Xylo-oligosaccharides Prebiotic / bifidogenic Prebiotic; 
Stimulate a healthy intestinal flora; 
Stimulates the growth of 
bifidobacteria. 
Conditions of use 
- 3 g/day 
- 2,6g/ day 
- Where a daily value is indicated the amount per serving is typicaly 25% unless otherwise 
stated 2.6g/day 
ID Food or Food constituent Health Relationship Proposed wording 
847 Beta-glucan of 
Saccharomyces cerevisiae 
Immune health  Beta glucan from yeast as 
immunomodulators 
Beta glucan from yeast support of 
natural defences 
Conditions of use 
- 400mg/d 
- 5 mg per kg body mass per day  
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1199 Black Currant juice Urinary tract maintenance 
(Urinary Calculus). 
Clarification provided 
Alkaline protective 
effect: increase citric acid 
excretion and contribute 
to support the urinary 
tract immune function. 
Blackcurrent juice helps to: 
- improve the urinary tract immune 
function. 
- support the normal functionning of 
the urinary tract. 
Conditions of use 
- One time 330 ml. 
ID Food or Food constituent Health Relationship Proposed wording 
1233 Brewer's yeast 
(Saccharomyces cerevisiae) 
Hair and nails health 
Clarification provided 
Useful in case of fragile nails. 
Helps to support the hair’s vitality. 
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Increase hair and nails 
resistance 
Helps to Improve the structure and 
appearance of hair and nails. 
Helps to support hair and nails 
health. 
Conditions of use 
- Saccharomyces cerevisiae At least 1g/day 
ID Food or Food constituent Health Relationship Proposed wording 
1265 Purple Grape Juice Blood flow/Vascular 
function 
Purple grape juice contributes to 
healthy arteries/ 
contributes to a healthy blood flow/ 
contributes to healthy vascular 
functions. 
Conditions of use 
- At least 250 ml per day 
Comments from Member States 
Purple grape juice contributes to healthy arteries/contributes to a healthy blood flow/contributes 
to healthy vascular functions. 
ID Food or Food constituent Health Relationship Proposed wording 
1267 Bran. Consumption of bran 
improves digestive 
function. 
Soodustab seedimist. 
Clarification provided 
Consumption of bran improves 
digestive function. 
Conditions of use 
- Küpsiste kliisisaldus on 5 g/100 g, väidet kasutava toidukäitleja poolt esitatud andmete 
põhjal on kliide päevane soovitatav kogus 31 g. 
Comments from Member States 
Consumption of bran improves digestive function. 
ID Food or Food constituent Health Relationship Proposed wording 
1342 Water-based product 
(Water purified by reverse 
osmosis to monomolecular 
level, complex of salts) 
Improves mechanical 
activity of gall- bladder 
Improves gallbladder 
mechanoactivity 
Conditions of use 
- ab 200 mg/l Sulfat (siehe EG Mineralwasser-Richtlinie) 
- 200- 400 ml in 30 - 40 min before eating 
ID Food or Food constituent Health Relationship Proposed wording 
1352 Name of Food product: 
Sqeez Wild Blueberry 
Juice Drink. 
Description of food in 
terms of food legislation 
Health benefits of food: 
Anti aging properties. 
Do benefits relate to a 
disease risk factor: No. 
Exact wording of claim as it appears 
on product: Blueberries have a wide 
range of health benefits including 
anti-ageing properties and the 
maintenance of urinary tract and 
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categories: food not 
covered by specific food 
legislation. 
Was food on Irish market 
before 1st July 2007: Yes. 
Target group: All of the 
general population 
including children and 
adults. 
vision health. 
Is claim a picture: No. 
Conditions of use 
- Does claim rely on the presence/presence in a reduced quantity/absence of a nutrient or 
other substance: Presence of a nutrient or other substance. Number of nutrients/other 
substances that are essential to claimed effect: 1. Names of nutrient/other substances and 
Quantity in Average daily serving: 200ml blueberry juice. Weight of average daily food 
serving: 200 mililitre(s). Daily amount to be consumed to produce claimed effect: 200 
mililitre(s). Number of food portions this equates to in everyday food portions: 1.00. Are 
there factors that could interfere with bioavailability: Yes. Please give reason: Storage 
beyond its shelf life. Length of time after consumption for claimed effect to become 
apparent: It is apparent immediately. Is there a limit to the amount of food which should be 
consumed in order to avoid adverse health effects: No.  
Comments from Member States 
Further clarification to support the use of this claim was not submitted to the Food Safety 
Authority of Ireland. 
ID Food or Food constituent Health Relationship Proposed wording 
1357 Name of Food product: 
Lentil & Bean Shoots. 
Description of food in 
terms of food legislation 
categories: food not 
covered by specific food 
legislation. 
Was food on Irish market 
before 1st July 2007: Yes. 
Health benefits of food: 
Naturally boost your 
digestive system. 
Do benefits relate to a 
disease risk factor: Yes. 
Target group: All of the 
general population 
including children and 
adults. 
Clarification provided 
Health benefits of food: 
High in fibre which helps 
maintain a healthy 
digestive system. 
Do benefits relate to a 
disease risk factor: Yes. 
Target group: All of the 
general population 
including children and 
adults. 
Exact wording of claim as it appears 
on product: Lentil & Bean Shoots 
naturally boost your digestive system. 
Is claim a picture: No. 
Conditions of use 
- Does claim rely on the presence/presence in a reduced quantity/absence of a nutrient or 
other substance: Presence of a nutrient or other substance. Number of nutrients/other 
substances that are essential to claimed effect: 1. Names of nutrient/other substances and 
Quantity in Average daily serving: 4.4 g fibre. Weight of average daily food serving: 40 
gram(s). Daily amount to be consumed to produce claimed effect: 40 gram(s). Number of 
food portions this equates to in everyday food portions: 1.00. Are there factors that could 
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interfere with bioavailability: No. Length of time after consumption for claimed effect to 
become apparent: It is apparent after a period of regular use. Number of days: 30 . Is there a 
limit to the amount of food which should be consumed in order to avoid adverse health 
effects: No. Where applicable outline nutritional composition (g per 100g) of food: Total 
Fat: 1.10. Saturated Fat: .20. Trans Fat: .00. Sugar: 17.00. Salt: .00. Sodium: .02.  
Comments from Member States 
Clarification/ further information/alternative wording which was provided by the FBO has been 
included. This FBO also includes information on the nutritional composition of the product 
carried out by an accredited laboratory - this is enclosed in a separate file identified by claim 
number - additional information. 
ID Food or Food constituent Health Relationship Proposed wording 
1368 Name of Food product: 
Sqeez Cranberry and 
Orange Juice Drink, Sqeez 
Light Cranberry Juice 
Drink. 
Description of food in 
terms of food legislation 
categories: food not 
covered by specific food 
legislation. 
Was food on Irish market 
before 1st July 2007: Yes. 
Health benefits of food: 
More recently, emerging 
research suggests that 
cranberries may also be 
powerful protectors of the 
stomach. 
Do benefits relate to a 
disease risk factor: No. 
Target group: All of the 
general population 
including children and 
adults. 
Exact wording of claim as it appears 
on product: More recently, emerging 
research suggests that cranberries 
may also be powerful protectors of 
our health in other areas of the body, 
such as the stomach, gums and even 
the heart. 
Is claim a picture: No. 
Conditions of use 
- Does claim rely on the presence/presence in a reduced quantity/absence of a nutrient or 
other substance: Presence of a nutrient or other substance. Number of nutrients/other 
substances that are essential to claimed effect: 1. Names of nutrient/other substances and 
Quantity in Average daily serving: 200 mililitres cranberry juice. Weight of average daily 
food serving: 200 mililitre(s). Daily amount to be consumed to produce claimed effect: 200 
mililitre(s). Number of food portions this equates to in everyday food portions: 1.00. Are 
there factors that could interfere with bioavailability: No. Length of time after consumption 
for claimed effect to become apparent: It is apparent immediately. Is there a limit to the 
amount of food which should be consumed in order to avoid adverse health effects: No.  
Comments from Member States 
Further clarification to support the use of this claim was not submitted to the Food Safety 
Authority of Ireland. 
ID Food or Food constituent Health Relationship Proposed wording 
1369 Name of Food product: 
Sqeez Wild Blurberry Juice 
Drink. 
Description of food in 
terms of food legislation 
categories: food not 
covered by specific food 
legislation. 
Was food on Irish market 
before 1st July 2007: Yes. 
Health benefits of food: 
Maintenance of urinary 
tract. 
Do benefits relate to a 
disease risk factor: No. 
Target group: All of the 
general population 
including children and 
adults. 
Exact wording of claim as it appears 
on product: Blueberries have a wide 
range of health benefits including 
anti-ageing properties and the 
maintenance of urinary tract and 
vision health. 
Is claim a picture: No. 
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Conditions of use 
- Does claim rely on the presence/presence in a reduced quantity/absence of a nutrient or 
other substance: Presence of a nutrient or other substance. Number of nutrients/other 
substances that are essential to claimed effect: 1. Names of nutrient/other substances and 
Quantity in Average daily serving: 200 mililitres blueberry juice. Weight of average daily 
food serving: 200 mililitre(s). Daily amount to be consumed to produce claimed effect: 200 
mililitre(s). Number of food portions this equates to in everyday food portions: 1. Are there 
factors that could interfere with bioavailability: Yes. Please give reason: Storage beyond its 
shelf life. Length of time after consumption for claimed effect to become apparent: It is 
apparent immediately. Is there a limit to the amount of food which should be consumed in 
order to avoid adverse health effects: No.  
Comments from Member States 
Further clarification to support the use of this claim was not submitted to the Food Safety 
Authority of Ireland. 
ID Food or Food constituent Health Relationship Proposed wording 
1379 Apple cider vinegar. Skin health. Helps maintain healthy skin. 
Conditions of use 
- Powder: 1,2 g. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1382 Brewer`s Yeast. Cardiovascular health. Strengthens the cardiovascular 
system, is necessary for blood 
formation. 
 
Conditions of use 
- 2- 4g. 
ID Food or Food constituent Health Relationship Proposed wording 
1383 Brewer`s Yeast Nervous system function 1. Helps maintain a healthy nervous 
system 
2. Stimulates mental and physical 
work capacities 
Conditions of use 
- 2- 4g 
- Traditional use of ale yeast, 3 table spoon of fresh yeast diluted in water or 4-10g of dried 
yeast per day 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1385 Brewer`s Yeast Skin health 
Clarification provided 
Improves the skin, hair 
and nail structure 
 
Improves skin, hair and nail 
condition 
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Conditions of use 
- 2- 4g 
Comments from Member States 
Brewer's yeast (Saccharomyces cerevisiae) contains B group vitamins and minerals (selenium, 
iron, copper, chromium), organic acids, amino acids, enzymes that improves the structure of 
skin, hair and nails. (EFSA published list of health claims - Nr.1233) 
ID Food or Food constituent Health Relationship Proposed wording 
1399 Stutenmilch, naturbelassen 
Clarification provided 
Mare’s milk, natural finish 
Stutenmilch fördert die 
Entwicklung der 
Bifidusflora im Darm, 
und stimuliert das 
Immunsystem. Wirksame 
Inhaltsstoffe sind u.a. 
Lactoferrin, Lysozym, 
Immunglobuline (sIgA, 
sIgM), weitere Enzyme 
(Amylase, Katalase, 
Lipase, Peroxydase, 
Phosphatase, Malat- u. 
Clarification provided 
Mare’s milk benefits the 
growth of intestinal 
bifidus bacteria and 
stimulates the immune 
system. Active 
components are 
lactoferrin, lysozyme, 
immunoglobulins 
(secretory 
immunoglobulin A, 
secretory 
immunoglobulin M), 
other enzymes (amylase, 
catalase, lipase, 
peroxydase, phosphatase, 
malat- and lactat-
dehydrogenase, lacto-
transferrin, acetylcholin), 
and beta-lactose, 
linolenic acid, vitamin C, 
taurine. 
[In German:] Stutenmilch kann die 
Anzahl an Bifidusbakterien im Darm 
erhöhen. 
Clarification provided 
Mare’s milk is able to increase the 
number of intestinal bifidus bacteria. 
Conditions of use 
- Naturbelassene, nicht erhitzte oder pasteurisierte Stutenmilch, die unter den Bedingungen 
für Vorzugsmilch erzeugt wurde und besonders keimarm ist. Sie ist bis zur Verwendung bei 
-18 °C tiefgekühlt 9 Monate lagerfähig. Besonders für Personen mit entzündli. 
ID Food or Food constituent Health Relationship Proposed wording 
1401 Mineralwasser/ 
Kohlensäure 
Verdauung/Magen-Darm- 
funktion (Anregung) 
[In german : ] regt die Verdauung an 
Clarification provided 
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Clarification provided 
mineral water/carbonic 
acid 
Clarification provided 
Digestion (stimulation) 
stimulates digestion 
Conditions of use 
- ab 1 g/l Kohlensäure 
- ab 2 g/l Kohlensäure 
ID Food or Food constituent Health Relationship Proposed wording 
1406 Natürliches Mineralwasser. 
Clarification provided 
Natural mineral water. 
Hautgesundheit. 
Clarification provided 
Skin health, in particular 
skin surface: significant 
reduction of skin density. 
[In German:] trägt zur sichtbaren 
Verbesserung der 
Hautoberflächenstruktur bei. 
Clarification provided 
Contributes to visible improvement 
of the skin surface structure. 
Conditions of use 
- 2 Liter (l)/Tag; min. 4 Wochen. 
- Zusammensetzung des Mineralwassers: Gesamtmineralisation mindestens 2,5 g /l, davon 
mindestens 1,8 g Hydrogencarbonat / l, mindestens 50 mg Magnesium /l, mindestens 90mg 
Calcium /l und mindestens 550 mg Natrium /l; Trinkmenge mindestens 2,25 l / Tag üb. 
Comments from Member States 
Additional example of wording: Can contribute towards improving skin surface structure; Can 
lead to a smoother skin surface structure. 
ID Food or Food constituent Health Relationship Proposed wording 
1477 Bovine lactoferrin Antimicrobial / antiviral / 
innate host defense 
Clarification provided 
Antimicrobial / antiviral / 
innate host defense. 
Inactivation of bacteria 
and virusses. 
Contribution to the 
aspecific immune 
defense. 
Contributes to the natural defences 
Conditions of use 
- Does claim rely on the presence/presence in a reduced quantity/absence of a nutrient or 
other substance: Presence of a nutrient or other substance Number of nutrients/other 
substances that are essential to claimed effect: 1 Names of nutrient/other substances and 
Quantity in Average daily serving: 65 micrograms selenium Daily amount to be consumed 
to produce claimed effect: 200 microgram(s) Are there factors that could interfere with 
bioavailability: Don't Know Length of time after consumption for claimed effect to become 
apparent: Habitual intakeIs there a limit to the amount of food which should be consumed 
in order to avoid adverse health effects: Don't Know 
- Does claim rely on the presence/presence in a reduced quantity/absence of a nutrient or 
other substance: Presence of a nutrient or other substance Number of nutrients/other 
substances that are essential to claimed effect: 1 Names of nutrient/other substances and 
Quantity in Average daily serving: 30mg Bovine Lactoferrin Daily amount to be consumed 
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to produce claimed effect: 200 miligram(s)Are there factors that could interfere with 
bioavailability: Yes Please give reason: Heat treatment of lactoferrin may result in 
denaturation of lactoferrin.Length of time after consumption for claimed effect to become 
apparent: It is apparent after a period of regular use. Number of days: 28 Is there a limit to 
the amount of food which should be consumed in order to avoid adverse health effects: 
NoOther conditions for use: Suggested intake ~ 30mg bovine lactoferrin/dose for 
antimicrobial & immune enhancing effects. 
- 160 mg for 10 day  
Comments from Member States 
Italy’s proposal is identical to Dutch proposal/ IE proposal is identical to Dutch proposal/ 
Slovak’s proposal is identical to the Dutch proposal 
ID Food or Food constituent Health Relationship Proposed wording 
1480 Bromelain Vascular health 
Clarification provided 
Vascular health. 
Maintains natural blood 
fluidity and vessel 
patency by helping to 
maintain balance of 
fibrinogen/plazmin 
system and to optimise 
bradikynin level.  
helps to maintein natural blood 
fluidity and vessel patence 
Conditions of use 
- daily dosage: >/= 200 mg (with activity 5 F 5 F.I.P/mg). 
- Personen, die eine Operation mit Verlust von Lymphknoten/Lymph-gefäßen hinter sich 
haben zur Langzeitverhütung von Ödemen––150 mg Bromelain– 
- 200 mg/Tag. tägl. Dosierung: ≥ 200 mg ( 5 F.I.P/mg).  
ID Food or Food constituent Health Relationship Proposed wording 
1482 Buckwheat extract 
containing flavonoid-
mineral (troxerutin - zinc) 
complex (Coldizin) 
Immune system function 
Clarification provided 
Improves the function of 
immune system cells 
Coldizin helps support the immune 
system 
Conditions of use 
- 50mg troxerutin and 25mg zinc gluconate (5 lozenges daily) 
ID Food or Food constituent Health Relationship Proposed wording 
1530 2 - Dimethylaminoethanol 
hydrogentartrate. 
For mental energy. Helps support mental development. 
Conditions of use 
- 25-200 mg 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1625 Nucleotides. Gastro-intestinal support. Dietary nucleotides help support a 
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healthy gastro-intestinal tract. 
Conditions of use 
- Typical adult dosage: 250 mg - 1000 mg exogenous RNA nucleotides, derived, for 
example, from Saccharomyces cerevisiae or other dietary sources. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1732 Inositol Nervous system function Important for the function of the 
nervous system. 
Conditions of use 
- 12-18 g per day 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1746 Para-aminobenzoic Acid  Essential part of the 
connective tissues, skin 
and hair 
helps maintain hair, nails and skin in 
optimum condition 
Conditions of use 
- 12 g daily in 4 to 6 divided doses  
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1777 Lecithin Function of the cell 
membrane 
1. Necessary for normal growth, 
wholesome mental and physical 
development 
2. Helps maintain functions and 
structure of the body and organ cell 
membranes 
3. Lecithin is found in every human 
cell and it participates in various 
vitally important processes 
Conditions of use 
- 1,2- 3,6 g 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1781 Pancreatic enzymes Digestive function For a better digestive process 
Conditions of use 
- 425 mg 
No clarifications provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1792 Beta-glucan (WGP) Immunity For immunity. 
Strengthens immunity. 
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Conditions of use 
- Food supplement with 125-150 mg of WGP beta-glucan (WGP = whole glucan particle) in 
the daily dose. 
No clarifications provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1795 Buffering salts (calcium 
carbonate + magnesium 
oxide) 
Clarification provided 
Food supplement for which 
health claims are 
requested:  
Sugarfree chewing gum 
with xylitol. 
The applicant wants to 
define the previously 
submitted conditions of use 
on Buffering salts (calcium 
carbonate + magnesium 
oxide), and add sodium 
bicarbonate to be one of 
the active ingredient.  
There are two different 
compositions of sugarfree 
chewing gum with xylitol, 
Composition I and 
Composition II. The 
ingredients of these two 
compositions are otherwise 
similar but  
Composition I contains as 
active ingredients only 1) 
calcium carbonate and 2) 
magnesium oxide whereas  
Composition II contains 1) 
calcium carbonate, 2) 
sodium bicarbonate and 3) 
magnesium oxide. 
List of ingredients of 
sugarfree chewing gum 
with xylitol (both 
Compositions I and II): 
- xylitol (35-37 %), 
chewing gum base, calcium 
carbonate (Compositions I 
and II), sodium bicarbonate 
(only Composition II), 
magnesium oxide 
Gut health Calms the stomach. 
In combination with the following 
sentence  
* Xylitol chewing gum for post-meal 
gastric acid attack.  
(or) 
* Xylitol gum with a fast and long-
lasting neutralising effect on gastric 
acids. 
Chewing calms your stomach. In 
combination with the following 
sentence: 
* Xylitol chewing gum for post-meal 
gastric acid attack. 
(or) 
* Xylitol gum with a fast and long-
lasting neutralising effect on gastric 
acids. 
Fast and long-lasting calming effect 
on your stomach. 
In combination with the following 
sentence  
* Xylitol chewing gum for post-meal 
gastric acid attack. 
* Calms the gastric acid attack 
* For gastric acid attack 
* Balances the gastric acids  
* Fast and long-lasting  
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(Compositions I and II), 
sorbitol/maltitol, flavours, 
thickener E414, humectant 
E422, emulcifier E322 
(rapeseed lecithin), colour 
E171, sweeteners E950 
and/or sucralose E955, 
glazing agents E903, E901, 
E904. 
One piece of xylitol 
chewing gum (ca. 1,4 
g/piece) will contain active 
ingredients as following: 
Composition I: 
300 mg of calcium 
carbonate (CaCO3) and 
100 mg of magnesium 
oxide (MgO) 
Composition II: 
100 mg of calcium 
carbonate (CaCO3), 150 
mg of sodium bicarbonate 
(NaHCO3) and 50 mg of 
magnesium oxide (MgO). 
These ingredients are 
situated in chewing gum 
base. 
Intake of 1-2 pieces of 
chewing gum just after the 
meal is recommended. The 
maximum daily dose is 6 
pieces for Composition I 
and 10 pieces for 
Composition II. To be 
chewed for at least 10 
minutes is recommended.  
Conditions of use 
- Xylitol chewing gum (food supplement) with 300-600 mg of calcium carbonate and 100-
200 mg of magnesium oxide in the edible dose (1-2 pieces of chewing gum). The chewing 
gum is sweetened with xylitol. 
Comments from Member States 
Food composition defined 
ID Food or Food constituent Health Relationship Proposed wording 
1814 Herbal yeast plasmolycate 
(saccharomyces 
cerevisiae). 
Absorption of nutrients. 
Clarification provided 
Herbal yeast 
plasmolysate promotes 
Promotes the absorption of nutrients. 
Helps the body utilise nutrients 
obtained from food more effectively. 
General and non-specific health claims 
 
45 EFSA Journal 2011; 9(6):2228 
absorption and helps the 
body to utilize nutrients 
obtained from the daily 
food more effectively. 
Conditions of use 
- Herbal yeast preparation with 2.7-4.5 g of herbal yeast plasmolycate (saccharomyces 
cerevisiae) in the daily dose. 
Comments from Member States 
Health relationship defined. 
ID Food or Food constituent Health Relationship Proposed wording 
1837 Pollen + Royal Jelly Sexual organs and/or 
hormone activity 
Balances hormone activity. 
For menopausal women. 
Conditions of use 
- Food supplement with 270mg of pollen and 190mg of Royal Jelly in the daily dose. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1842 Protease, lipase and other 
enzymes that break down 
carbohydrates 
Clarification provided 
Protease, lipase and other 
enzymes that break down 
carbohydrates 
Proteolytic enzyme 
product, one capsule 
contains: 
Protease 4.5 21000 HUT 
(hemoglobin unit on 
tyrosine basis) 
Protease 3.0 40,7 SAPU 
(spectrophotometric acid 
protease unit) 
Protease 6.0 4000 HUT 
(hemoglobin unit on 
tyrosine basis) 
Capsules are taken with 
meals. 
Enzyme product with 
protease, lipase and 
different carbohydrates 
breaking enzymes, one 
capsule contains: 
Amylase 7500 DU 
(dextrinizing unit) 
Digestion 
Clarification provided 
Product with protease 
enzyme: Promotes 
digestion. The 
preparation´s enzymes 
break down proteins. 
Product´s protease 
enzymes split proteins 
derived from food to 
complement the 
weakening secretion of 
organism´s own enzyme 
production. 
Product with protease, 
lipase and carbohydrate 
breaking enzymes: 
Promotes digestion. The 
preparation´s enzymes 
break down proteins, fats 
and carbohydrates. 
Product´s different 
enzymes split proteins, 
fats and carbohydrates 
derived from food to 
complement the 
weakening secretion of 
organism´s own enzyme 
production; Diminishes 
gas production and other 
symptoms derived from 
Promotes digestion The preparation’s 
enzymes break down proteins. A 
food supplement containing protease 
enzymes is particularly recommended 
after heavy meals and, as the years 
pass, to complement the weakening 
secretion of enzymes that break down 
proteins. 
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Protease 4.5  18000 HUT 
(hemoglobin unit on 
tyrosine basis) 
Glucoamylase  10 AGU  
(amyloglucocidase unit) 
Protease 6.0  5000 HUT  
(hemoglobin unit on 
tyrosine basis) 
Protease 3.0  10 SAPU  
(spectrophotometric acid 
protease unit) 
Lipase RO   437.5 FIP  
(federatin international 
pharmaceutique) 
Cellulase 125 CU  
(cellulase unit)  
Malt diastase  250 DP o  
(degrees diastatic power) 
Invertase 250 SU  (Sumner 
unit) 
Capsules are taken with 
meals. 
indigestion.  
Conditions of use 
- Food supplement containing protease enzymes (protease 2.5 18000 HUT, protease 3.0 10 
SAPU and protease 6.0 4000 HUT units/daily dose and proteases, lipases and enzymes that 
break down carbohydrates (amylase 7500 DU, glucoamylase 10 AGU, cellulase 125 CU, 
malt diastase 250 DP and invertase 250 SU, lipase RO 437.5 FIP units/daily dose. 
ID Food or Food constituent Health Relationship Proposed wording 
1859 Soy isoflavones + lycopene 
+ zinc + selenium + 
vitamin D + vitamin E + 
vitamin C 
Sexual organs and/or 
hormone activity 
Clarification provided 
A carefully considered 
combination of important 
isoflavones, vitamins and 
minerals promotes men´s 
wellbeing. 
Good for the prostate gland. 
A carefully considered combination 
of important isoflavones, vitamins 
and minerals for men’s well-being. 
Name of symbol included in the 
claim: MenBalans®. 
Conditions of use 
- Preparation with 2.5 g/100g, 40 mg/day of isoflavones, 93.8 mg/100g, 1.5 mg/day of 
lycopene, 938 mg/100 g, 15 mg/day of zinc, 3125 µg /100g, 50 µg/day of selenium, 313 
µg/100 g, 5 µg/day of vitamin D, 625 mg/100g, 10 mg/day of vitamin E and 3750 mg/100 
g, 60 mg/day of vitamin C. 
The amount and quality of microbial flora in the gut can affect the usefulness of the 
isoflavones. 
Comments from Member States 
Health relationship defined 
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ID Food or Food constituent Health Relationship Proposed wording 
1879 Name of Food product: 
gelatin & cystine 
Description of food in 
terms of food legislation 
categories: Food 
supplement 
Was food on Irish market 
before 1st July 2007: No 
Health benefits of food: 
healthy hair, skin and 
nails 
Do benefits relate to a 
disease risk factor: No 
Target group: All adults 
aged 18 years and over 
Exact wording of claim as it appears 
on product: gelatin, cystine  
significantly strengthens hair, skin 
and nails 
Examples of any alternative wording 
that may be used in relation to claim: 
Gelatin and cystine significantly 
increases hair diameter and the 
degree of hardness of finger and toe 
nails. 
Is claim a picture: No 
Conditions of use 
- Number of nutrients/other substances that are essential to claimed effect: 2. Names of 
nutrient/other substances and Quantity in Average daily serving: 100mg Gelatin, 100mg L-
cystine.  Weight of average daily food serving:   300 miligram(s). Daily amount to be 
consumed to produce claimed effect:   300 miligram(s). Number of food portions this 
equates to in everyday food portions:     3. Are there factors that could interfere with 
bioavailability: Yes. Please give reason: do not store above 25 degrees C. Length of time 
after consumption for claimed effect to become apparent: It is apparent after a period of 
regular use. Number of days: 7 Is there a limit to the amount of food which should be 
consumed in order to avoid adverse health effects: Don't Know 
ID Food or Food constituent Health Relationship Proposed wording 
1906 Fat-reduced cream powder 
(rich source of milk 
phospholipids) 
Clarification provided 
Fat-reduced cream powder 
(rich source of milk 
phospholipids) 
≥ 2g milk phospholipids, 
corresponding to 10g 
Lacprodan PL-20, per 
eating occasion 
Gastrointestinal health 
Clarification provided 
Gastrointestinal health 
Protects the stomach 
lining from excessive 
stomach acid 
• For people with a sensitive 
stomach;  
• Soothes a sensitive stomach; 
• Protects the stomach lining 
Conditions of use 
- ≥2g milk phospholipids per eating occasion 
Comments from Member States 
Additional comment Dutch applicant: Fat-reduced cream powder (Lacprodan PL-20) contains 
about 20% milk phospholipids (from milk fat globule membranes). It may be used as an 
ingredient in a variety of foods. In order to not increase the fat intake, it is used preferably as a 
substitute for other fat components of food. 
Portugal's proposal and additional comment is identical to the Dutch proposal and comment 
ID Food or Food constituent Health Relationship Proposed wording 
1944 Beta-glucan of 
Saccharomyces cerevisiae 
Immune health 
Clarification provided 
Beta glucan from yeast as 
immunomodulators 
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Promotes a healthy 
immune system by 
notably increasing IgA  
Beta glucan from yeast support of 
natural defences 
Conditions of use 
- 400mg/d 
ID Food or Food constituent Health Relationship Proposed wording 
1950 Collagen Skin health Collagen is a natural component of 
the skin. 
Helps the skin to preserve its 
firmness and elasticity. 
Has beneficial effect in the 
maintenance of skin firmness and 
elasticity. 
Conditions of use 
- At least 30 mg per day. 
ID Food or Food constituent Health Relationship Proposed wording 
1998 Aronia melanocarpa 
(Common Name : 
Chokeberry ) 
Vein health/Vascular 
health 
Maintenance of blood vessel wals 
strenght 
Conditions of use 
- Frucht /  Äquivalent zumAnthocyanin - Gehalt von 9-15 g frischer Früchte; täglich (45 – 60 
mg Anthocyanine ber. als Cyanidin-3-0-galactosid pro Tag) 
- Fruit / The equivalence of anthocyanins content of 9-15 g of fresh fruits per day (45 – 60 
mg anthocyanins calculated as cyanidin-3-0 galactoside per day) 
ID Food or Food constituent Health Relationship Proposed wording 
2175 Capsicum annum 
(Common Name : 
Capsicum) 
Stomach health Helps to protect the stomach in case 
of intake of irritating substances 
Conditions of use 
- owoc/ równowartość 90-360mg na dzień 
- Fruit / The equivalent to 90-360 mg per day 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
2212 Ananas comosus - common 
name : Bromelain, 
Pineapple 
Vascular and Vein Health "Used for the good circulation of 
blood in microvessels"  
"Helps to decrease the sensations of 
heavy leggs" 
Conditions of use 
- Traditional use of the fruit / 80-320mg of bromelain two to three times daily for 8 to 10 
days / Equivalent quantity in extract 
- Fruit / 160-960 mg of bromelain daily for 8 to 10 days / Equivalent quantity in extract 
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Comments from Member States 
claim 1998 has the same relationship and comment 0 
ID Food or Food constituent Health Relationship Proposed wording 
2223 Armoracia rusticana Intestinal health Soothes the digestive tract/ 
/helps support the digestive system 
/a source of mucilage which support 
the mucous membranes 
Conditions of use 
- Root / The equivalent of 6-20 g of root per day 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
2329 Raphanus sativus  - 
common name : radish, 
black radish, Japanese 
radish, Daikon 
Digestion "Used to facilitate the digestion"  
"Helps to support normal liver 
function"  
"Contributes to the stimulation of the 
production of the digestive body 
fluids"  
"Supports the liver and biliary 
function"  
"Contributes to the digestive 
comfort" 
"Helps to facilitate fat digestion"  
"Contributes to better fat digestion"  
"Helps to support the digestion"  
"Contributes to support the 
digestion". 
Conditions of use 
- Traditional use of the root / 50 - 100 ml of pressed juice daily /  Equivalent quantity in 
extract 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
2487 Rubus idaeus (Raspberry) Menstrual health A traditional lady’s tea, particularly 
recommended during menopause and 
menstruation 
Conditions of use 
- Leaf: 0,2 g / Used as part of a multibotanical combination 
No clarification provided by Member States 
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ID Food or Food constituent Health Relationship Proposed wording 
2504 Zea mays (Maize) Liver health 1. For liver and gallbladder health — 
beneficially affects the function of 
liver and gallbladder 
2. A beneficial effect in case of acute 
condition of chronic pancreatitis 
3. Beneficially affects digestion and 
promotes body’s detoxification 
processes 
Conditions of use 
- Extract: 10 mg / Corn: 60 mg, Stigma: 40 mg / Used as part of a multibotanical 
combination 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
2552 Levure de bière  Epiderme. 
Soigne l'acnée 
Contribue à la beauté de la peau 
Favorise l'éclat et la vitalité de la 
peau 
Conditions of use 
- 750mg/jour 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
2743 Papaya (Carica papaya L.) Skin curves/ Cellulitis Helps to reduce localized excess fat. - 
Helps to limit cellulitis thanks to its 
proteolytic effect. 
Conditions of use 
- 400 mg per day, documentation do not evidence data supporting the active dose to be 
specifically recommended. 
- Leaves or fruit. At least 1g per day leaves powder 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
2753 Sureau: Elder berry (dry 
aqueous extract) 
Veinous system Improves blood circulation. 
Contributes to improve blood 
circulation 
Conditions of use 
- 40 mg of dry aqueous elder berry extract per day. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
2759 Brocoli : Dry extract of 
concentrated Brassica 
oleracea inflorescences 
juice 
Gastric acidities Help in case of eructation.  
Regulating action on gastric 
acidities/acidities of the stomach. 
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Protective role against the gastric 
aggressions and their nuisances. 
Conditions of use 
- Plant / 600mg of extract per day 
ID Food or Food constituent Health Relationship Proposed wording 
2773 Graines de brocoli et 
extraits de graines de 
brocoli: Sulforaphane 
Santé de la prostate Le sulforaphane aide à maintenir la 
fonction de la prostate. Il contribue à 
la fonction normale de la prostate. Il 
aide à maintenir votre prostate en 
forme 
Conditions of use 
- Graines et  extraits de graines de brocoli / équivalent  de 100 à 500 mg de sulforaphane  par 
jour 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
2825 Papaya Digestion Supports pancreas activity and 
protein break-up. 
Papaya breaks down proteins and 
relieves after a heavy meal and when 
traveling in areas with different food 
hygiene. 
The papain enzymes in papaya break 
down proteins and activates digestive 
enzymes. 
Conditions of use 
- Food supplement with 0.78-1.56 g of papaya in the daily dose. 
- Leaves 
At least 1 g per day 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
2886 Natural mineral water: 
Hydrogencarbonates as Na- 
, Mg-, Ca-, salts: NaHCO3, 
Mg(HCO3)2,Ca(HCO3)2 
Stomach acid in digestion Hydrogencarbonates neutralize 
stomach acid. 
Conditions of use 
- 15% RDA per 100 ml 
Comments from Member States 
MS clarification to Cou: 'min. 1300 mg HCO3- /L, 200 mL to 350 mL three times during the day 
ID Food or Food constituent Health Relationship Proposed wording 
2916 Indole-3-carbinol Cell metabolism - 
positively affects the 
fission of cells their 
Indole-3-carbinol supports the 
defence ability of female 
reproductive organs (ovaria, uterus, 
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immunity and 
regeneration 
Clarification provided 
Support  to balance the 
level of sex hormones in 
human body needed  for 
correct function of 
reproductive organs 
breasts). Indole-3-carbinol helps to 
support the healthy development and 
fission of soft tissues of male and 
female reproductive organs, stomach, 
colon and larynx.  
Conditions of use 
- 150 - 450mg daily 
ID Food or Food constituent Health Relationship Proposed wording 
3076 Beta carota (carrot juice, 
lactic acid fermented) 
Intestinal flora Supports a healthy intestinal and 
colon flora 
Conditions of use 
- At least 1 glass ( = 150 ml) lactic acid fermented carrot juice per day 
ID Food or Food constituent Health Relationship Proposed wording 
3087 Dietary food for special 
medical purposes - oral 
rehydrating solution with 
decreased osmolarity 
composed according to 
WHO/UNICEF 
recommendations - 
ORSALIT. 
ORSALIT is available in 
following versions: 
- ORSALIT without flavor, 
- ORSALIT with banana 
flavor, 
- ORSALIT with raspberry 
flavor. 
• The composition of 
ORSALIT - in accordance 
with current 
WHO/UNICEF 
recommendations: 
glucose– 75 mmol/l, 
sodium– 75 mmol/l, 
chlorides– 65 mmol/l, 
potassium– 20 
mmol/l,citrate– 10 mmol/l, 
osmolarity– 245 mOsm/l 
• 100g of the product in 
sachets contain: glucose 
61,84 g, chlorides 10,55 g, 
citrate 8,65 g, sodium 7,89 
ORSALIT is given in 
order to supplement 
liquids and mineral 
components during 
diarrhea and/or vomiting 
1. ORSALIT is used in all cases 
when dehydration may occur 
2. ORSALIT is hypoosmolar, oral 
rehydrating solution composed 
according to  WHO and UNICEF 
recommendations 
3. ORSALIT helps to avoid 
dehydration which may occur in case 
of diarrhea and/or vomiting 
4. ORSALIT uses mechanism of 
collective adsorption of water, 
sodium and glucose which is not 
damaged even during diarrhea 
5. ORSALIT is used in order to 
supplement current losses of water 
and electrolytes 
6. Oral rehydrating solutions are used 
in every situation when dehydration 
may occur 
7. ORSALIT  composition is 
identical to current recommendations 
of WHO and UNICEF 
8. ORSALIT composition ensures 
effective rehydration during diarrhea 
on the contrary of usually given feezy 
drinks (cola), apple juice or broth 
9. ORSALIT rehydrates effectively 
during diarrhea, on the contrary to 
traditional methods 
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g,  potassium 3,58 g. 
• 100 ml of the product 
prepared according to the 
instructions of use contain: 
glucose1,35 g, chlorides 
0,23 g, citrate 0,19 g, 
sodium 0,17 g, potassium 
0,08 g. 
ORSALIT with raspberry 
flavor and ORSALIT with 
banana flavor  contain 
aroma additionally. 
10. Oral rehydration is beneficial and 
well tolerated due to low risk of side 
effects 
11. ORSALIT is used in order to 
rehydrate 
12. ORSALIT is dedicated to infants, 
children and adults rehydration 
during diarrhea and/or vomiting 
13. ORSALIT is dedicated to 
supplement  body fluids and mineral 
components 
14. ORSALIT is used in case of 
disturbance of water-electrolyte 
balance during dehydration due to 
diarrhea and/or vomiting 
Conditions of use 
- Jak w oświadczeniu nr 1. 
- Ilość produktu, dobowa dawka oraz czas stosowania produktów ORSALIT, które wpływają 
na wywołanie efektu zdrowotnego, są uzależnione od wieku, masy ciała i fazy nawadniania. 
W zależności od fazy nawadniania przewiduje się następujący schemat nawadniania: a) Faza 
nawadniania – pierwsze 3-4 godziny nawadniania: • masa ciała do 8 kg (wiek: do 6 
miesięcy) – 2 saszetki rozpuszczone zgodnie z zaleceniem (400 ml), • masa ciała od 8 do 12 
kg (wiek: od 6 miesięcy do 1 roku) - 3 saszetki rozpuszczone zgodnie z zaleceniem (600 
ml), • masa ciała od 12 do 15 kg (wiek: od 1 roku do 2 lat) - 4 saszetki rozpuszczone 
zgodnie z zaleceniem (800 ml), • masa ciała powyżej 15 kg (wiek: powyżej 2 lat) - 6 
saszetek rozpuszczonych zgodnie z zaleceniem (1200 ml), • osoby dorosłe – 4-8 saszetek 
rozpuszczonych zgodnie z zaleceniem (500-1500 ml); b) Faza nawadniania 
podtrzymującego (dalsze etapy nawadniania): • masa ciała do 12 kg (wiek: do 1 roku) - 1 
saszetka rozpuszczona zgodnie z zaleceniem (200 ml); należy podawać 100 ml po każdym 
biegunkowym stolcu lub wymiotach, • masa ciała powyżej 12 kg (wiek: powyżej 1 roku) - 1 
saszetka rozpuszczona zgodnie z zaleceniem (200 ml); należy podawać po każdym 
biegunkowym stolcu lub wymiotach. 2. Uwagi dotyczące  stosowania preparatów ORSALIT 
: • powinny  być przyjmowane pod nadzorem lekarza, w przypadku wystąpienia biegunki 
i/lub wymiotów, • nie zawierają białka mleka, laktozy i glutenu, • w trakcie przyjmowania 
preparatów można kontynuować karmienie piersią lub podawanie standardowych mieszanek 
mlecznych, • nie można stosować pozajelitowo, • nie powinny być stosowane u osób, u 
których nie występuje odwodnienie organizmu lub zagrożenie odwodnienia, • 
przeciwwskazania: wstrząs hemodynamiczny, niedrożność jelit, • mogą być stosowane u 
niemowląt, dzieci i osób dorosłych, • ORSALIT o smaku neutralnym przeznaczony jest dla 
niemowląt poniżej 6 miesiąca życia oraz dla dzieci i dorosłych skłonnych do alergii. 
- 25 mmol/l (460 mg/l) ≤ sód (Na+) ≤ 50 mmol/l (1150 mg/l). Claim to be only used for Foods 
for sportpeople under the Dir. 89/398/EEC Metabolisable carbohydrates: ≥ 75% of total 
energy. 340kJ/l (80kcal/l) ≤ Energy ≤ 1488kJ/l (350kcal/l). 20 mmol/l (460 mg/lbrazu, a 
następnie ponowne wstawienie go. 
ID Food or Food constituent Health Relationship Proposed wording 
3128 Arabinoxylan Immune system 
Clarification provided 
Contributes to maintain 
immunological defences 
Natural enhancer of immune system.  
Supports the immune system. 
Supports the immune response.  
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and immune system 
function, such as the 
action of Natural Killer 
cell activity 
Support of the body's defence. 
Conditions of use 
- Arabinoxylan from corn husk or rice bran. Dose range: 15-45 mg/kg. 
ID Food or Food constituent Health Relationship Proposed wording 
3131 hyaluronic acid helps to keep elasticity of 
skin 
Clarification provided 
Hyaluronic is major 
component of skin, binds 
water, moisturizes skin 
from inside out and 
provides moisture and 
elasticity of skin.   
helps to keep good health of skin  
helps to keep young look of skin 
 
Conditions of use 
- 100 mg per day 
ID Food or Food constituent Health Relationship Proposed wording 
3137 Digestive enzyme protease, 
lipase, amylase, 
glucoamylase, invertase, 
cellulase, malt diastase 
Break down of high-
molecules compound 
from food 
Clarification provided 
helps to digest food {in 
case of deteriorated 
digest functions} == 
claim referring to 
reduction of digest 
problem risk 
Helps to encrease bioavailability of 
nutritient from food, supports vitality 
and activity of organism, break down 
the foods we eat into basic building 
blocks that our body then absorbs 
and reassembles to build cells, 
tissues, organs, glands, and body 
systems and to reuse for more 
metabolic process 
Conditions of use 
- 75 mg of amylase per day, 2,5 mg of invertase per day, 3,13 mg of cellulase per day, 36 mg 
of protease per day, 8,75 mg of lipase per day, 3,09 mg of malt diastase per day, 22,22 mg 
of glucoamylasw per day 
ID Food or Food constituent Health Relationship Proposed wording 
3153 MGN-3 Rice Bran 
Arabinoxylan compound    
Strengthens  immune 
systems   
Clarification provided 
Necessary to maintain a 
strong immune system 
and to keep optimal NK-
cell activity―. 
Strengthens  immune 
systems   
Increases NK-cell, T and 
Helps the body maintain a strong 
immune system  
Supports optimal immune functions. 
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B lymphocyte activity 
Conditions of use 
- 1000-3000mg daily 
ID Food or Food constituent Health Relationship Proposed wording 
3164 Lactoferrin Skin health  
Clarification provided 
Lactoferrin has been 
shown to express several 
properties which are 
relevant to the prevention 
and treatment of acne; 
these properties include 
anti-microbial, anti-
inflammatory and anti-
oxidant effects.  
Lactoferin favourably affect skin 
status/improve external skin status 
Conditions of use 
- 160 mg for 8 weeks  
ID Food or Food constituent Health Relationship Proposed wording 
3519 Pleurotus Eryngii pancréas régule la physiologie du pancréas et 
le métabolisme des graisses 
Conditions of use 
- 2 gélules le matin avant le repas 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
3667 Citrus sinensis - common 
name : Orange 
Vascular and Vein Health "Traditionally used for the good 
circulation of blood in microvessels" 
/ "Traditionally used to decrease the 
sensations of heavy leggs" / "Used 
for the good circulation of blood in 
microvessels" / "Helps to decrease 
the sensations of heavy leggs"  
Conditions of use 
- Traditional use of the outer peel : 2,5-5 g/d 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
3687 Pineapple (Ananas 
comosus L.) 
Skin curves/ Cellulitis Helps to reduce localized excess fat. - 
Helps to limit cellulitis thanks to its 
proteolytic effect. 
Conditions of use 
- Stem or fruit- at least 1200 mg per day 
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ID Food or Food constituent Health Relationship Proposed wording 
3692 Prunus cerasus - common 
name : Sour cherry 
Digestion "Traditionally used to facilitate the 
digestion" / "Used to facilitate the 
digestion" / "Contributes to the 
digestive comfort" / "Helps to 
support the digestion" / "Contributes 
to support the digestion".    
Conditions of use 
- Traditional use of the fruit and pedoncule of fruit : 5-10 g/d 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
3972 Aegle marmelos UNRIPE 
FRUIT 
Digestion Supports digestion and metabolism of 
carbohydrates and lipids 
Conditions of use 
- Powder: 1.0-0.10g/day 
All over 2 years old:  2-4 years ¼ adult dose, 4-10 years half adult dose 
ID Food or Food constituent Health Relationship Proposed wording 
4112 Reishi mushrooms 
(Ganoderma lucidum) and 
extracts 
Immune support 
Clarification provided 
Immune health: induces 
cytokine production (e.g. 
TNF-alpha and IFN-
gamma) 
Reishi mushrooms [Reishi mushroom 
extracts] may help to support the 
immune system 
Conditions of use 
- Typical adult dosages: 2 – 6 g raw fungus daily or 600 – 1800 mg, three times a day. Use 
cautiously or following advice of a healthcare professional if taking anticoagulant 
medication (e.g. warfarin). 
ID Food or Food constituent Health Relationship Proposed wording 
4202 Gélatine Hair beauty and health Promote keratin formation. 
Strength hair. 
Hair is more resistant and thick. 
Increase hair resistance. 
Conditions of use 
- 160 mg/day 
ID Food or Food constituent Health Relationship Proposed wording 
4241 Huile de noisettes: Hazel 
nut (Corylus avellana) oil 
Skin care Provides an essential fatty acid 
entering the composition of the scalp. 
Provides an essential fatty acid 
entering the composition of the skin. 
Conditions of use 
- 315 mg/day of Corylus avellana oil 
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No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
4243 Huile de foie de Morue: 
Cod liver oil standardized 
in vitamin A, EPE and HA 
Skin care Maintain the youth capital of the 
skin. Contribute to the integrity of the 
skin tissues 
Conditions of use 
- 550 to 1100 mg of oil 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
4247 Corn protein hydrolysate 
titrated at 29 % glutamine 
Overtraining and effort 
prevention 
Can help to prevent the consequences 
of overtraining in athletes.   
Can help to prevent the outbreak of 
the effort 
Conditions of use 
- 2,2 g dose/physical exercise (= 638 mg glutamine) 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
4248 Corn protein hydrolysate 
titrated at 29 % glutamine 
Physical performance Can help to improve physical 
performance 
Conditions of use 
- 2,2 g dose/physical exercise (= 638 mg glutamine) 
ID Food or Food constituent Health Relationship Proposed wording 
4278 Black currant (Ribes 
nigrum L.) 
Vein health Support of venous circulation -  
Helps to reduce the feeling of tired 
and heavy legs -  
Helps to maintain healthy leg-vein 
functions -  
Promotes circulatory well-being -  
Favourable influence on the blood 
circulation -  
For legs relief and to favour comfort 
Conditions of use 
- Fruit At least 1 g of fruit juice per day or an equivalent extract 
ID Food or Food constituent Health Relationship Proposed wording 
4407 Ganoderma lucidum-
Mashroom-Reishi 
mushroom 
Physical Well-being Stimulates the body in exhaustion 
Conditions of use 
- 150 – 350 mg a day 
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ID Food or Food constituent Health Relationship Proposed wording 
4662 Bromelain Digestive system benefits Digestive aid, protein digestion  
Conditions of use 
- Oral administration, capsules or tablets 
ID Food or Food constituent Health Relationship Proposed wording 
4691 Papain  Digestive system benefits Digestive aid, protein digestion 
Conditions of use 
- Oral administration, capsules or tablets 
 
